---
title: An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease
euct_id: 2022-500424-30-00
phase: Phase 4
status: Completed
sponsor: UCB Biopharma
canonical_url: "https://parkinsonspathways.com/trials/eu/2022-500424-30-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2022-500424-30-00"
ctis_last_updated: "2026-04-22T03:41:24.903550153"
source: EU Clinical Trials Information System (CTIS)
---
# An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease

**EU CT Number:** [2022-500424-30-00](https://euclinicaltrials.eu/ctis-public/view/2022-500424-30-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Completed
- **Sponsor:** UCB Biopharma
- **Start Date:** 2022-11-21
- **Completion Date:** 2027-04-05
- **Conditions:** Parkinson’s disease, Parkinson's disease
- **Interventions:** UCB0599 PRD4385815, Placebo matching UCB0599 and without active substance, IODINE IOFLUPANE (123I)

## Member States

Trial is authorized in 6 member states: France, Germany, Italy, Netherlands, Poland, Spain.

## Sites (47)

- NeuroKlinika Gabinet Lekarski Prof. Andrzej Bogucki, Lodz, Poland
- Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. sp. k., Oswiecim, Poland
- Pratia Jelenia Gora, Jelenia Gora, Poland
- Centrum Medyczne Neuroprotect, Warsaw, Poland
- Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, Katowice, Poland
- Michalski I Partnerzy Lekarze sp.p., Cracow, Poland
- Krakowskie Centrum Medyczne Sp. z o.o., Cracow, Poland
- Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p., Lublin, Poland
- Centrum Medyczne Neuromed Sp. z o.o., Bydgoszcz, Poland
- Mtz Clinical Research Powered By Pratia, Warsaw, Poland
- Etg Neuroscience Sp. z o.o., Warsaw, Poland
- Assistance Publique Hopitaux De Paris, Creteil Cedex, France
- CHRU de Strasbourg – Hôpital de Hautepierre, Strasbourg, France
- Centre Hospitalier Universitaire De Nantes, Saint Herblain, France
- Hopital Purpan, Toulouse Cedex 9, France
- CHRU Lille - Hopital Roger Salengro, Lille Cedex, France
- Carthera, Paris, France
- Centre Hospitalier Universitaire De Nimes, Nimes Cedex 9, France
- Assistance Publique Hopitaux De Marseille, Marseille Cedex 05, France
- Pellegrin Hospital, Bordeaux, France
- Stichting Radboud University Medical Center, Nijmegen, Netherlands
- Charite Universitatsmedizin Berlin KöR, Berlin, Germany
- University Of Regensburg, Ratisbon, Germany
- Neuro Centrum Science GmbH, Erbach, Germany
- Medizinische Hochschule Hannover, Hanover, Germany
- Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR, Mainz, Germany
- Universityclinic Giessen And Marburg GmbH, Marburg, Germany
- University Of Erlangen Nuremberg, Erlangen, Germany
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden, Germany
- Katholische Kliniken Ruhrhalbinsel gGmbH, Essen, Germany
- University Medical Centre Schleswig-Holstein, Kiel, Germany
- Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V., Bonn, Germany
- Curiositas ad sanum Studien- und Beratungs GmbH Innklinikum Haag i.OB, Haag i. OB, Germany
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
- Azienda Ospedaliera S Maria Di Terni, Terni, Italy
- Azienda Ospedaliera Policlinico Universitario Tor Vergata, Rome, Italy
- Azienda Ospedaliera Di Padova, Padova, Italy
- Irccs San Raffaele Roma S.r.l., Rome, Italy
- Hospital Universitario Hm Puerta Del Sur, Mostoles, Spain
- Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Hospital Ruber Internacional, Madrid, Spain
- Complexo Hospitalario Universitario A Coruna, A Coruna, Spain
- Policlinica Gipuzkoa, Donostia, Spain
- Hospital Clinic De Barcelona, Barcelona, Spain
- Hospital Universitario Reina Sofia, Cordoba, Spain
- Hospital Universitario Virgen De La Macarena, Sevilla, Spain
- University Clinic Of Navarra, Pamplona, Spain

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s disease; Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2022-500424-30-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2022-500424-30-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2022-500424-30-00*